Health Care & Life Sciences » Biotechnology | Circassia Pharmaceutical PLC

Circassia Pharmaceutical PLC | Income Statement

Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
10,800.00
23,100.00
46,300.00
48,300
Cost of Goods Sold (COGS) incl. D&A
-
24.00
7,200.00
13,300.00
14,900.00
13,300
Gross Income
-
24.00
3,600.00
9,800.00
31,400.00
35,000
SG&A Expense
24,796.00
45,789.00
67,100.00
53,600.00
116,100.00
72,200
EBIT
24,796.00
45,813.00
63,500.00
-
84,700.00
37,200
Unusual Expense
271.00
-
2,900.00
1,000.00
28,100.00
9,600
Non Operating Income/Expense
-
178.00
1,800.00
5,200.00
1,100.00
9,200
Interest Expense
21.00
18.00
-
100.00
100.00
100
Pretax Income
23,940.00
43,907.00
62,900.00
38,800.00
113,600.00
55,800
Income Tax
3,913.00
8,881.00
12,800.00
1,900.00
20,000.00
9,200
Equity in Affiliates
46.00
82.00
100.00
-
-
-
Consolidated Net Income
19,981.00
35,108.00
50,000.00
36,900.00
93,600.00
46,600
Net Income
19,981.00
35,108.00
49,900.00
36,800.00
93,600.00
46,600
Net Income After Extraordinaries
19,981.00
35,108.00
49,900.00
63,700.00
88,100.00
23,900
Net Income Available to Common
19,981.00
35,108.00
49,900.00
137,300.00
99,100.00
117,100
EPS (Basic)
0.11
0.21
0.20
0.48
0.31
0.34
Basic Shares Outstanding
187,422.40
169,118.80
249,578.50
284,889.20
319,541.50
344,347.30
EPS (Diluted)
0.11
0.21
0.20
0.48
0.31
0.34
Diluted Shares Outstanding
187,422.40
169,118.80
249,578.50
284,889.20
319,541.50
344,347.30
EBITDA
24,796.00
45,789.00
60,600.00
38,500.00
79,800.00
32,800
Non-Operating Interest Income
606.00
1,746.00
1,700.00
900.00
400.00
300
Minority Interest Expense
-
-
100.00
100.00
-
-

About Circassia Pharmaceutical

View Profile
Address
Northbrook House
Oxford Oxfordshire OX4 4GA
United Kingdom
Employees -
Website http://circassia.com
Updated 07/08/2019
Circassia Pharmaceuticals Plc is a biopharmaceutical company, which engages in the development and commercialization of allergy, asthma, and respiratory products. It operates through the following segments: NIOX, Respiratory, and US AZ Collaboration. The NIOX segment provides a portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.